Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial


Senan S., ÖZGÜROĞLU M., Daniel D., Villegas A., Vicente D., Murakami S., ...More

ESMO OPEN, vol.7, no.2, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 7 Issue: 2
  • Publication Date: 2022
  • Doi Number: 10.1016/j.esmoop.2022.100410
  • Journal Name: ESMO OPEN
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
  • Keywords: immunotherapy, radiation therapy, chemotherapy, surgery, multimodality therapy, RANDOMIZED CONTROLLED-TRIAL, PHASE-III, PREOPERATIVE CHEMOTHERAPY, INDUCTION CHEMOTHERAPY, SURGICAL RESECTION, RADIOTHERAPY, N2, SURGERY
  • Istanbul University Affiliated: No

Abstract

Background: The phase III PACIFIC trial (NCT02125461) established consolidation durvalumab as standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC) and no disease progression following chemoradiotherapy (CRT). In some cases, patients with stage IIIA-N2 NSCLC are considered operable, but the relative benefit of surgery is unclear. We report a post hoc, exploratory analysis of clinical outcomes in the PACIFIC trial, in patients with or without stage IIIA-N2 NSCLC.